User profiles for "author:J Chataway"

Joanna Chataway

STEaPP, UCL
Verified email at ucl.ac.uk
Cited by 4781

[HTML][HTML] Attitudes to vaccination: a critical review

…, S Castle-Clarke, N Sevdalis, J Chataway - Social science & …, 2014 - Elsevier
This paper provides a consolidated overview of public and healthcare professionals'
attitudes towards vaccination in Europe by bringing together for the first time evidence …

Multiple sclerosis progression: time for a new mechanism-driven framework

…, MP Amato, B Banwell, F Barkhof, J Chataway… - The Lancet …, 2023 - thelancet.com
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Secondary progressive multiple sclerosis: new insights

BAC Cree, DL Arnold, J Chataway, T Chitnis, RJ Fox… - Neurology, 2021 - AAN Enterprises
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …

A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22

…, R Feakes, J Gray, N Smaldon, J Chataway… - Nature …, 1996 - nature.com
The population prevalence of multiple sclerosis is 0.1% 1; however, the risk of the disease in
the siblings of affected individuals is very much higher at 3–5% 2, 3. The importance2 of …

[HTML][HTML] Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled …

J Chataway, N Schuerer, A Alsanousi, D Chan… - The Lancet, 2014 - thelancet.com
Background Secondary progressive multiple sclerosis, for which no satisfactory treatment
presently exists, accounts for most of the disability in patients with multiple sclerosis …

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

…, DR Altmann, R Brenner, J Chataway… - The Lancet …, 2010 - thelancet.com
Background Partial blockade of voltage-gated sodium channels is neuroprotective in
experimental models of inflammatory demyelinating disease. In this phase 2 trial, we aimed …

Inclusive innovation: an architecture for policy development

J Chataway, R Hanlin, R Kaplinsky - Innovation and Development, 2014 - Taylor & Francis
The past two decades have been characterized by an increasing uncoupling of economic
growth and social and economic development. Outside of China, the numbers living in …

Psychological distress after stroke and aphasia: the first six months

…, J Marshall, RD Wiggins, J Chataway… - Clinical …, 2010 - journals.sagepub.com
Objective: We explored the factors that predicted psychological distress in the first six
months post stroke in a sample including people with aphasia. Design: Prospective …

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

D Ontaneda, RJ Fox, J Chataway - The Lancet Neurology, 2015 - thelancet.com
Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability
independent of relapses and can occur with disease onset (primary progressive) or can be …

[HTML][HTML] Multiple sclerosis, a treatable disease

A Doshi, J Chataway - Clinical Medicine, 2017 - ncbi.nlm.nih.gov
This article reviews our current understanding and modern treatment of multiple sclerosis
(MS). MS is a disabling condition resulting in devastating social and economic impacts. As …